- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
CD55 Antibody 5B9E1 / Decay Accelerating Factor Antibody targets CD55, a membrane-associated complement regulatory protein commonly known as decay-accelerating factor (DAF). CD55 protects host cells from complement-mediated damage by accelerating the dissociation of C3 and C5 convertases, thereby limiting amplification of the complement cascade. The protein belongs to the regulators of complement activation family and contains four extracellular complement control protein domains. Its predominant membrane-associated form is attached to the cell surface through a glycosylphosphatidylinositol (GPI) anchor, positioning CD55 to regulate complement activity directly at the plasma membrane. Alternative transcript processing can also produce soluble forms of the protein.
CD55 regulates complement activation through the classical, lectin, and alternative pathways. In the classical and lectin pathways, it promotes dissociation of C2a from the C4b2a convertase, while in the alternative pathway it facilitates displacement of Bb from C3bBb. These activities shorten convertase lifetimes and reduce downstream complement amplification. CD55 acts at an earlier stage of the cascade than CD59, which inhibits assembly of the membrane attack complex. Together with other complement regulatory proteins, CD55 helps distinguish protected host surfaces from targets susceptible to complement-mediated injury. Its activity is particularly important where circulating complement components encounter cellular membranes.
Deficient CD55 expression contributes to disorders involving inappropriate complement activation. In paroxysmal nocturnal hemoglobinuria, acquired defects in GPI-anchor biosynthesis result in the loss of multiple surface proteins, including CD55 and CD59, from affected blood cells. The resulting vulnerability to complement-mediated injury contributes to disease pathology. Inherited CD55 deficiency causes CHAPLE disease, a disorder associated with complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy. CD55 also carries antigens of the Cromer blood group system, linking its molecular structure to clinically relevant erythrocyte surface determinants.
CD55 expression has been investigated in cancer, inflammation, infection, and transplantation. Increased expression on certain tumor cells may reduce their susceptibility to complement-dependent immune attack, although the biological consequences vary among tumor types and microenvironments. CD55 can also participate in cellular interactions through binding partners such as ADGRE5/CD97. Its extensive glycosylation influences the apparent molecular weight of the mature protein and contributes to variation in electrophoretic migration. CD55 Antibody 5B9E1 supports investigation of complement regulation, membrane protein expression, and the cellular mechanisms that influence susceptibility to immune-mediated injury.
For a published monoclonal antibody targeting this complement regulatory protein, see our CD55 Antibody clone 143-30.
Optimal dilution of the CD55 Antibody 5B9E1 / Decay Accelerating Factor Antibody should be determined by the researcher.
Recombinant human CD55 protein (amino acids D35-K347) was used as the immunogen for the CD55 antibody.
After reconstitution, the CD55 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
Decay-accelerating factor antibody, DAF antibody, complement decay-accelerating factor antibody, complement regulatory protein CD55 antibody, complement control protein CD55 antibody, CD55 antigen antibody, CD55 glycoprotein antibody, GPI-anchored CD55 antibody, membrane decay-accelerating factor antibody, Cromer blood group antigen antibody, CD55 complement inhibitor antibody, complement regulator DAF antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.